Category: Leukemia
| Intervention | Condition | Outcome / Effect | Source | ||
|---|---|---|---|---|---|
| 📊 |
Achievement of systemic leukemia complet
vs No achievement of systemic leu |
Acute myeloid leukemia |
Patients who achieved systemic leukemia complete remission had a significantly higher probability of
89% vs. 58% |
↑ | PMC8711723 |
| 📊 |
CXCR4 inhibitor
vs no CXCR4 inhibitor |
Acute myeloid leukemia
Acute Myeloid Leukemia Patient |
CXCR4 inhibitors mobilize AML cells and enhance the efficacy and duration of response to induction c
not quantified |
↑ | 3465702 |
| 💬 | Use of FLT3 inhibitors in treating AML p | Acute myeloid leukemia | FLT3 N676K mutations in AML are sensitive to contemporary FLT3 inhibitors, leading to longer median |
CXCR4 inhibitors are used in acute myeloid leukemia to mobilize AML cells and enhance the efficacy and duration of response to induction chemotherapy, although the effect size is not quantified. (3465702) FLT3 inhibitors are prescribed for AML patients with FLT3 N676K mutations, and anecdotal reports suggest these drugs lead to longer median survival. (Reddit) Achieving systemic leukemia complete remission, often through induction chemotherapy, is associated with a higher probability of CNS leukemia complete remission (89% vs. 58%). (PMC8711723)